CLSA bullish on Dixon Technologies, highlights Vivo JV and margin expansion; maintains Rs 19,365 target
The brokerage noted that Dixon's Q1 results came in above expectations, reinforcing confidence in the company's growth outlook. CLSA highlighted that Dixon has reiterated its FY26 smartphone shipment guidance at 41–43 million units, a significant jump from 28 million units achieved in FY25.
According to the report, future growth drivers include the recently announced Vivo joint venture , growing exports, and expansion in other verticals. CLSA expects Dixon's component manufacturing ramp-up to contribute meaningfully to margin expansion—even after the PLI benefits phase out in FY27.
With strong visibility across business segments and operating leverage in play, CLSA remains bullish on Dixon's medium-term prospects.
Disclaimer: The brokerage views expressed above are those of CLSA. This article does not constitute investment advice. Readers are advised to consult their financial advisor before making any investment decisions.
Ahmedabad Plane Crash
News desk at BusinessUpturn.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
20 hours ago
- Business Upturn
SBI Life share: CLSA sees 20% upside on strong VNB margin and improving product mix
CLSA bullish on SBI Life, margin expands to 27.4% in Q1, target set at ₹2,180 By Arunika Jain Published on July 25, 2025, 08:01 IST Last updated July 25, 2025, 08:05 IST CLSA has maintained an Outperform rating on SBI Life Insurance, assigning a target price of ₹2,180, which implies an upside of nearly 20% from the current market price of ₹1,817.00. The brokerage highlighted that SBI Life delivered a strong performance in Q1FY26, marked by a robust Value of New Business (VNB) margin of 27.4%, an improvement of 60 basis points year-on-year. The margin expansion was primarily driven by a favourable product mix, particularly a shift away from Unit-Linked Insurance Plans (ULIPs) toward higher-margin protection and non-par products. CLSA noted that while Annualized Premium Equivalent (APE) growth for the quarter stood at 9% YoY, it was partially dragged down by a flat performance in the agency channel. Despite this, management remains confident of achieving mid-teens APE growth for FY26, underpinned by channel diversification and better productivity. SBI Life continues to benefit from its strong distribution footprint, robust parentage, and improved product profitability, CLSA added. Disclaimer: The views expressed in this article are those of the brokerage firm (CLSA) and do not constitute investment advice. Investors are advised to consult a certified financial advisor before making any investment decisions. Ahmedabad Plane Crash Arunika Jain, a graduate in Mass Communication, brings a fresh perspective to the world of journalism. Arunika has a passion for writing finance and corporate news at You can write to her at [email protected]
Business Upturn
2 days ago
- Business Upturn
Dr. Reddy's shares jump over 3% following Q1 results – Should you buy, hold or sell? Know More
By Aditya Bhagchandani Published on July 24, 2025, 09:37 IST Shares of Dr. Reddy's Laboratories surged 3.06% to Rs 1,285.60 on Wednesday after the company reported its Q1 FY26 financial results. The stock touched an intraday high of Rs 1,287.90 and now commands a market capitalization of Rs 1.07 lakh crore. For the quarter ended June 30, 2025, the pharmaceutical major posted a consolidated net profit of Rs 1,418 crore, up 2% year-on-year. Revenue from operations stood at Rs 8,545 crore, reflecting an 11% YoY increase, primarily driven by contributions from the acquired Nicotine Replacement Therapy (NRT) portfolio and steady performance in branded markets. However, profit declined 11% quarter-on-quarter, while revenue remained flat sequentially. EBITDA for the quarter was Rs 2,280 crore, marking a 5% YoY increase, though EBITDA margin slipped 530 basis points to 56.9%, largely due to pricing pressure in the US generics segment and lower operating leverage. The Global Generics segment recorded Rs 7,560 crore in revenue, up 10% YoY, but remained unchanged QoQ. Revenue from North America declined 11% YoY to Rs 3,410 crore amid price erosion in key generics like Lenalidomide. Meanwhile, India revenue grew 11% YoY to Rs 1,470 crore, aided by new launches and pricing strategies. European business saw a sharp 142% YoY jump to Rs 1,270 crore, driven by the NRT acquisition and product launches. Brokerages offered a cautious outlook on Dr. Reddy's Laboratories following its Q1 FY26 results, primarily due to concerns over the US generics business. CLSA and Jefferies both retained their 'Underperform' ratings, with target prices of Rs 1,120 and Rs 1,100 respectively. CLSA noted that while overall earnings were in line with expectations, the US base business is expected to remain flat or grow in low single digits year-on-year, with Revlimid sales likely tapering off from Q3FY26. Jefferies flagged a miss in Q1 estimates due to a sharper-than-expected decline in US sales, driven by lower revenues from gRevlimid and sustained pressure in the base portfolio. Elevated SG&A and R&D spending also weighed on margins. However, it highlighted upcoming launches such as gOzempic in Canada and the US filing for Abatacept as key triggers to watch. Meanwhile, Morgan Stanley maintained an 'Equal-weight' rating with a target price of Rs 1,298, acknowledging steady growth in most markets but citing generic price erosion and reduced operating leverage as drag factors on margin. Dr. Reddy's Q1 YoY Comparison Table (in Rs crore): Metric Q1 FY26 Q1 FY25 YoY % Change Revenue from Operations 8,545 7,700 11% Net Profit 1,418 1,390 2% EBITDA 2,280 2,170 5% EBITDA Margin (%) 56.9% 62.2% -530 bps Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
2 days ago
- Business Upturn
Dr Reddy's stock: CLSA, Jefferies recommend sell, Morgan Stanley says hold — here's why
By Arunika Jain Published on July 24, 2025, 08:40 IST Top brokerages have delivered a mixed outlook on Dr. Reddy's Laboratories following its Q1FY26 results. While Jefferies and CLSA retained their Underperform ratings citing concerns over U.S. business momentum and gRevlimid tapering, Morgan Stanley maintained an Equal-Weight stance with a ₹1,298 target. CLSA: Cautious on U.S. growth taper CLSA kept an Underperform rating with a target of ₹1,120, saying Q1 earnings were in line with estimates. However, it expects the U.S. base business to be flat or grow at low single digits, and noted that gRevlimid sales could start tapering from Q3FY26. The potential launch of Semaglutide in Canada and India may partly offset this slowdown, CLSA added. Jefferies: Q1 miss, watching key launches Jefferies also retained an Underperform rating with a lower target of ₹1,100, citing a Q1 miss due to a decline in U.S. sales, particularly gRevlimid and the base business. SG&A and R&D expenses stayed elevated. However, Jefferies is watching two key pipeline catalysts: the approval of gOzempic in Canada and U.S. filing for Abatacept, which it believes could meaningfully contribute to revenue if launched on time. Morgan Stanley: Balanced view Morgan Stanley took a more neutral stance with an Equal-Weight rating and a target price of ₹1,298. It noted that Q1 revenue grew 11% YoY, but gross margins declined due to higher price erosion and lower operating leverage. EBITDA was in line, while PAT rose 2% YoY. Morgan Stanley believes the risk-reward remains balanced. Disclaimer: The brokerage views expressed above are solely those of the respective firms. This article does not constitute investment advice. Readers are advised to consult their financial advisor before making any investment decisions. Ahmedabad Plane Crash Arunika Jain, a graduate in Mass Communication, brings a fresh perspective to the world of journalism. Arunika has a passion for writing finance and corporate news at You can write to her at [email protected]
